Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
Boess FG, Scelsi MA, Grimmer T, Perry RJ, Tonietto M, Klein G, Hofmann C, Salami M, Wojtowicz J, Lansdall CJ, Lane C, Kerchner GA, Smith J, Doody RS. Boess FG, et al. Among authors: doody rs. J Prev Alzheimers Dis. 2024;11(3):537-548. doi: 10.14283/jpad.2024.60. J Prev Alzheimers Dis. 2024. PMID: 38706270 Clinical Trial.
Gantenerumab in Early Alzheimer's Disease. Reply.
Bateman RJ, Smith J, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. Among authors: doody rs. N Engl J Med. 2024 Feb 29;390(9):867. doi: 10.1056/NEJMc2314291. N Engl J Med. 2024. PMID: 38416440 No abstract available.
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Brockmann K, Svoboda H, Trundell D, Monnet A, Doody R, Fontoura P, Kerchner GA, Brundin P, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Nat Med. 2024 Apr;30(4):1096-1103. doi: 10.1038/s41591-024-02886-y. Epub 2024 Apr 15. Nat Med. 2024. PMID: 38622249 Free PMC article.
Long-Term Safety of Gantenerumab in Participants with Alzheimer's Disease: A Phase III, Double-Blind, and Open-Label Extension Study (Marguerite RoAD).
Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS. Neve A, et al. Among authors: doody rs. J Alzheimers Dis. 2024;101(1):353-367. doi: 10.3233/JAD-240221. J Alzheimers Dis. 2024. PMID: 39177596 Free PMC article. Clinical Trial.
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.
Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, Simuni T, Postuma RB, Pavese N, Stocchi F, Brockmann K, Smigorski K, Gerbaldo V, Fontoura P, Doody R, Kerchner GA, Brundin P, Marek K, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Nat Med. 2024 Dec;30(12):3669-3675. doi: 10.1038/s41591-024-03270-6. Epub 2024 Oct 8. Nat Med. 2024. PMID: 39379705 Free PMC article. Clinical Trial.
Long-term safety of gantenerumab in participants with Alzheimer's disease: A phase III, open-label extension study (SCarlet RoAD).
Boada M, Neve A, Das B, Wojtowicz J, Huang Z, Bullain S, Watkin M, Lott D, Bittner T, Delmar P, Klein G, Hofmann C, Kerchner GA, Smith J, Baudler M, Fontoura P, Doody RS. Boada M, et al. Among authors: doody rs. J Alzheimers Dis. 2024 Dec 16:13872877241303644. doi: 10.1177/13872877241303644. Online ahead of print. J Alzheimers Dis. 2024. PMID: 39686620
Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease.
Wise-Brown A, Brangman SA, Henderson JN, Willis-Parker M, Monroe S, Mintzer JE, Grundman M, Smith J, Doody RS, Lin H, Assman B, Rippon GA, Gonzales R, Assunção SS. Wise-Brown A, et al. Among authors: doody rs. EClinicalMedicine. 2024 Jul 13;73:102693. doi: 10.1016/j.eclinm.2024.102693. eCollection 2024 Jul. EClinicalMedicine. 2024. PMID: 39429811 Free PMC article. Review.
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.
Nikolcheva T, Pagano G, Pross N, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Seppi K, Monnet A, Shariati N, Ricci B, Rutten-Jacobs L, Respondek G, Kustermann T, Taylor KI, Trundell D, Fontoura P, Doody R, Svoboda H, Bonni A; PADOVA Investigators and Prasinezumab Study Group. Nikolcheva T, et al. Parkinsonism Relat Disord. 2024 Dec 29;132:107257. doi: 10.1016/j.parkreldis.2024.107257. Online ahead of print. Parkinsonism Relat Disord. 2024. PMID: 39798255 Free article.
396 results